cab 1

P-CAB agent 1 (compound B19) is a potassium-competitive acid blocker with an IC50 of 60.50 nM for H+ K+-ATPase, used in the study of acid-related diseases (ARDs).

P-CAB Agent 2 is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor that effectively inhibits H+/K+-ATPase activity, showing an IC50 value of <100 nM. It also demonstrates inhibition of the hERG potassium channel with an IC50 value of 18.69 M, indicating no acute toxicity. P-CAB Agent 2 effectively curbs histamine-induced gastric acid secretion [1].

Mecbotamab vedotin (BA3011) is a humanized IgG1-κ antibody engineered to target the AXL receptor tyrosine kinase (AXL). Serving as a conditionally active biologic (CAB), mecbotamab is conjugated to monomethyl auristatin E (MMAE) through a cleavable linker, creating an antibody-drug conjugate (ADC) for therapeutic use [1] [2].

P-CAB agent 2 hydrochloride is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor. It effectively inhibits H+ K+-ATPase activity, with an IC50 value of <100 nM, and targets the hERG potassium channel with an IC50 value of 18.69 μM. Moreover, P-CAB agent 2 hydrochloride demonstrates no acute toxicity and effectively inhibits histamine-induced gastric acid secretion [1].

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].